Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Grab Holdings Ltd. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Grab Holdings Ltd. trades at $3.95 (market cap $16.07B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.5× Grab Holdings Ltd.'s market cap, and Grab Holdings Ltd. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | GRAB | |
|---|---|---|
Market Cap | $39.89B | $16.07B |
Sector | Health | Technology |
52-Week High | $491.22 | $6.45 |
52-Week Low | $278.09 | $3.27 |
Enterprise Value | $38.15B | $11.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Grab Holdings trades at $3.93, up 1.29% with a bullish technical signal. The company achieved profitability in 2025 with $268M net income and 7.95% margin, showing strong revenue growth from $2.8B to $3.4B. Analyst consensus is strongly bullish with 11 buy ratings and a $5.45 price target, representing 39% upside potential. Recent news highlights investor interest despite Uber CEO's board departure causing temporary volatility.
Grab presents a compelling growth story with improving fundamentals and strong analyst support. Key opportunities include Southeast Asia market expansion and super-app ecosystem growth. Risks include intense competition, execution challenges, and market volatility. The stock offers significant upside to consensus targets but requires monitoring of quarterly execution and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
